Abstract

BackgroundConventional Cardiopulmonary Bypass (cCPB) is a trigger of systemic inflammatory reactions, hemodilution, coagulopathy, and organ failure. Miniaturised Cardiopulmonary Bypass (mCPB) has the potential to reduce these deleterious effects. Here, we describe our standardised ‘Hammersmith’ mCPB technique, used in all types of adult cardiac operations including major aortic surgery.MethodsThe use of mCPB remains limited by the diversity of technologies which range from extremely complex, micro systems to ones very similar to cCPB. Our approach is designed around the principle of balancing the benefits of miniaturisation; reducing foreign surface area while maintaining patient safety.ResultsFrom January 2010 to March 2011, a single surgeon performed 184 consecutive operations (Euro score Logistic 8.4+/-9.9): 61 aortic valve replacements, 78 CABGs, 25 aortic valve replacement and CABG and 17 other procedures (major aortic surgery, re-do operations or double/triple valve replacements).Our clinical experience suggests that:i. Venous drainage is optimally maintained using kinetic energy.ii. Venous collapse pressure depends on the patient’s anatomy and cannula size, but most importantly on the negative pressure generated by venous drainage.iii. The patient-prime interaction is optimised with antegrade and retrograde autologous priming, which mixes the blood and prime away from the tissues and results in a reduced oncotic destabilization.iv. mCPB is a safe and reproducible techniqueConclusionThe Hammersmith mCPB is a “next generation” system which uses standard commercially available components. It aims to maintain safety margin and the benefit of miniaturised system whilst reducing the human factor demands.

Highlights

  • Conventional Cardiopulmonary Bypass is a trigger of systemic inflammatory reactions, hemodilution, coagulopathy, and organ failure

  • The applicability of these findings was limited by the diversity of Miniaturised Cardiopulmonary Bypass (mCPB) technologies evaluated in the randomized controlled trial (RCT), which ranged from extremely complex, micro systems to ones very similar to Conventional Cardiopulmonary Bypass (cCPB) technology

  • We describe our Hammersmith mCPB system initially used by a single surgeon (JA) and progressively adopted by the rest of the unit surgeons

Read more

Summary

Introduction

Conventional Cardiopulmonary Bypass (cCPB) is a trigger of systemic inflammatory reactions, hemodilution, coagulopathy, and organ failure. Miniaturised Cardiopulmonary Bypass (mCPB) has the potential to reduce these deleterious effects. RCTs have consistently reported benefits of mCPB, including reductions in length of stay in the intensive care unit, lower blood loss and transfusion requirements, improved renal and neurological outcomes [2,3,4,5], a higher mean arterial pressure during CPB, a lower consumption of vasoactive drugs, and a reduced inflammatory response. A meta-analysis of 33 RCTs showed mCPB to be associated with a lower risk of blood loss, postoperative stroke, and mortality compared to cCPB [6]. The applicability of these findings was limited by the diversity of mCPB technologies evaluated in the RCTs, which ranged from extremely complex, micro systems to ones very similar to cCPB technology

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call